Open-Label, Phase 2, Multicenter Feasibility Study of MDMA-Assisted Therapy for PTSD in Europe Timeline
First Participant Screened in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
On July 18, 2022, the first UK participant in our open-label Phase 2 study of MDMA-assisted therapy for PTSD was screened by the research team at the Institute of Psychiatry, Psychology & Neuroscience …
Screening Begins in Phase 2 MDMA-Assisted Therapy Study of Participants with PTSD in Berlin and London
The MAPS Europe team is delighted to announce that screening of participants for our open-label Phase 2 study of MDMA-assisted therapy for PTSD has begun at the Charité – Universitätsmedizin Berlin …
Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
MAPS Europe is delighted to announce that on March 23, 2022, the first site in the United Kingdom was activated and will begin screening patients in our open-label Phase 2 study of MDMA-assisted therapy …
Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
MAPS Europe is delighted to announce that as of March 7, 2022, recruitment of patients into the MP18 study began at the Department of Psychiatry and Neurosciences in the Charité – Universitätsmedizin …
Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
MAPS is Granted Innovation Passport in United Kingdom for MDMA as an Adjunct to Therapy for PTSD
FOR IMMEDIATE RELEASE MDMA as an adjunct to therapy for PTSD is the forty-first treatment to receive the Innovation Passport since its inception in January 2021 The designation is intended to accelerate …
Enrollment Continues in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
As of January 2022, sites in The Netherlands and the Czech Republic are continuing to enroll patients for our Phase 2 study, an optional fMRI sub-study assessing changes in brain activity in subjects with …
First Session Conducted in Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with PTSD in Europe
We are very excited to share updates for the open-label lead-in study of MDMA-assisted therapy for PTSD in Europe, including news about enrollment progress and first MDMA-assisted therapy session! Data …
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder: January 2021 Update
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …
An Open-Label, Phase 2, Multicenter Feasibility Study of Manualized MDMA-Assisted Therapy with an Optional fMRI Sub-Study Assessing Changes in Brain Activity in Subjects with Posttraumatic Stress Disorder
Taking place in the United Kingdom, Germany, Portugal, Norway, the Czech Republic, and the Netherlands, this open-label Phase 2 study of MDMA-assisted therapy for PTSD will serve as the lead-in to the …